<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01361711</url>
  </required_header>
  <id_info>
    <org_study_id>NU 10H06</org_study_id>
    <secondary_id>NCI-2011-00514</secondary_id>
    <secondary_id>STU00044115</secondary_id>
    <nct_id>NCT01361711</nct_id>
  </id_info>
  <brief_title>Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia</brief_title>
  <official_title>A Phase 2 Trial of Alemtuzumab-Ofatumumab Combination in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Comprehensive Cancer Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies the side effects and how well giving alemtuzumab and ofatumumab&#xD;
      together works in treating patients with previously untreated chronic lymphocytic leukemia&#xD;
      (CLL). Monoclonal antibodies, such as alemtuzumab and ofatumumab, can block cancer growth in&#xD;
      different ways. Some block the ability of cancer to grow and spread. Others find cancer cells&#xD;
      and help kill them or carry cancer killing substances to them. Giving alemtuzumab together&#xD;
      with ofatumumab may kill more cancer cells&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. To determine the efficacy and safety of alemtuzumab-ofatumumab combination treatment in&#xD;
      previously untreated CLL.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive alemtuzumab subcutaneously (SC) three times a week in weeks 1-18 and&#xD;
      ofatumumab intravenously (IV) over 4-6 hours on day 1 of weeks 3, 5, 7, 9, 11, 13, 15, and&#xD;
      17.&#xD;
&#xD;
      After completion of study treatment, patients are followed up for up to 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Actual">August 17, 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best Response as Defined by the iwCLL2008 (International Workshop on Chronic Lymphocytic Leukemia 2008)</measure>
    <time_frame>Range of responses between 8 weeks from initiation of treatment to 2 months post-treatment.</time_frame>
    <description>CR= Absence of clonal lymphocytes in the peripheral blood, significant lymphadenopathy, hepatomegaly or splenomegaly, and constitutional symptoms. Blood counts: Neutrophils ≥ 1,500/μL; Platelets &gt;100,000μL; Hemoglobin &gt; 11.0g/dL. Bone marrow normocellular for age, less than 30% of nucleated cells = lymphocytes. Lymphoid nodules absent. CRi= Fulfills CR but anemia or thrombocytopenia or neutropenia related to drug toxicity. PR= 2 criteria from group A and 1 from Group B. Group A: Decrease in the number of blood lymphocytes of 50% or more. Reduction in lymphadenopathy. No increase in any lymph node, and no new enlarged lymph node. A decrease in liver by at least 50% from baseline. Decrease in the size of the spleen by 50% or more. Reduction in marrow infiltrate or B-lymphoid nodules. Group B: Platelet counts &gt; than 100,000/μL or 50% better. Hemoglobin &gt; than 11.0g/dL or 50% better. Neutrophils&gt;1500/μL or 50% better. Criteria is continued in Analysis Population Description below...</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival Rates</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Survival rates will be calculated for progression-free survival (PFS), therapy-free survival (TFS), and overall survival (OS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Toxicity as Measured by Adverse Events Experienced While on Treatment</measure>
    <time_frame>Weeks 1, 3, 5, 7, 9, 11, 13, 15, and 17</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of Disease Characteristics With Disease Outcomes</measure>
    <time_frame>At baseline and over 18 weeks</time_frame>
    <description>Clinical outcomes (such as response, PFS and TFS) will be correlated with pre-treatment clinical and biological characteristics(such as Rai staging, presence of bulky lymph nodes, cytogenetics by FISH, CD38, ZAP70 and IgVH mutation status).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare Efficacy Between This Study and Historical Control Study of Alemtuzumab-rituximab</measure>
    <time_frame>At baseline and over 18 weeks</time_frame>
    <description>Response and survival rates will be compared between the two studies.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Stage I Chronic Lymphocytic Leukemia</condition>
  <condition>Stage II Chronic Lymphocytic Leukemia</condition>
  <condition>Stage III Chronic Lymphocytic Leukemia</condition>
  <condition>Stage IV Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>Treatment (monoclonal antibody therapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive alemtuzumab SC three times a week in weeks 1-18 and ofatumumab IV over 4-6 hours on day 1 of weeks 3, 5, 7, 9, 11, 13, 15, and 17.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>alemtuzumab</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Treatment (monoclonal antibody therapy)</arm_group_label>
    <other_name>anti-CD52 monoclonal antibody</other_name>
    <other_name>Campath-1H</other_name>
    <other_name>MoAb CD52</other_name>
    <other_name>Monoclonal Antibody Campath-1H</other_name>
    <other_name>Monoclonal Antibody CD52</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ofatumumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (monoclonal antibody therapy)</arm_group_label>
    <other_name>Arzerra</other_name>
    <other_name>HuMax-CD20</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biopsy</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (monoclonal antibody therapy)</arm_group_label>
    <other_name>biopsies</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must be Eastern Cooperative Oncology Group (ECOG) performance status 0-2&#xD;
&#xD;
          -  Patients must have a confirmed diagnosis of CLL as defined by the International&#xD;
             Workshop on CLL (iwCLL) 2008 (iwCLL2008) criteria below:&#xD;
&#xD;
          -  Presence of at least 5x10^9 B lymphocytes/L (5000/uL) in the peripheral blood&#xD;
&#xD;
          -  Morphologically, the lymphocytes must appear of small to moderate size with &lt; 55%&#xD;
             prolymphocytes, atypical lymphocytes or lymphoblasts&#xD;
&#xD;
          -  The clonality and immunophenotype of the circulating B-lymphocytes must be confirmed&#xD;
             by flow cytometry to express CD5, CD23, CD19, CD20, CD52 and either kappa or lambda&#xD;
             light chain&#xD;
&#xD;
          -  Patients must have symptomatic disease requiring therapy; indications for therapy are&#xD;
             defined by the iwCLL2008 criteria as follows (one or more are sufficient):&#xD;
&#xD;
          -  Clinical manifestations (if believed by the investigator to be caused by CLL): a)&#xD;
             Unintentional weight loss &gt; 10% within the previous 6 months; b) significant fatigue;&#xD;
             c) fevers of greater than 100.5 degrees Fahrenheit (F) (38 degrees Celsius [C]) for 2&#xD;
             weeks without evidence of infection; d) night sweats without evidence of infection&#xD;
&#xD;
          -  Evidence of progressive marrow failure as manifested by the development or worsening&#xD;
             of anemia (&lt; 11 g/dl), thrombocytopenia (&lt; 100,000/mm^3) or neutropenia (&lt; 1,500/mm^3)&#xD;
&#xD;
          -  Massive (i.e. &gt; 6 cm below left costal margin) or progressive splenomegaly&#xD;
&#xD;
          -  Massive nodes/clusters (&gt; 5 cm) or progressive symptomatic adenopathy&#xD;
&#xD;
          -  Progressive lymphocytosis with an increase of &gt; 50% over 2 month period, or an&#xD;
             anticipated doubling time of less than 6 months&#xD;
&#xD;
          -  NOTE: Marked hypogammaglobulinemia or the development of a monoclonal protein in the&#xD;
             absence of any of the above criteria for active disease is not sufficient for protocol&#xD;
             therapy&#xD;
&#xD;
          -  Patients must have evidence of adequate bone marrow reserve as shown by absolute&#xD;
             neutrophil count (ANC) of at least 1,000/mm^3; however, if the cytopenias are due to&#xD;
             extensive bone marrow involvement by CLL, patients may be included in the study&#xD;
&#xD;
          -  And patients must have evidence of adequate bone marrow reserve as shown by platelet&#xD;
             count of at least 50,000/mm^3; however, if the cytopenias are due to extensive bone&#xD;
             marrow involvement by CLL, patients may be included in the study&#xD;
&#xD;
          -  Serum creatinine must be less than 2.0 mg/dl obtained within 2 weeks prior to study&#xD;
             enrollment; if serum creatinine is greater than 1.5 mg/dl, the creatinine clearance&#xD;
             calculated from a 24 hour urine collection must be greater than 40 ml/min&#xD;
&#xD;
          -  Total bilirubin must be less than 2 mg/dl (unless due to CLL involvement of liver or a&#xD;
             known history of Gilbert's disease)&#xD;
&#xD;
          -  Aspartate aminotransferase (AST), alanine aminotransferase (ALT) must be no more than&#xD;
             2.5 times upper limit of normal unless due to disease involvement of the liver&#xD;
&#xD;
          -  Alkaline phosphatase must be no more than 2.5 times upper limit of normal unless due&#xD;
             to disease involvement of the liver&#xD;
&#xD;
          -  All patients must have given a signed, informed consent prior to enrollment on study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior cytotoxic therapies are NOT allowed; the only exception is prior corticosteroid&#xD;
             therapy (prednisone up to 1 mg/kg for =&lt; 3 months) which must be stopped at least 1&#xD;
             week prior to study enrollment&#xD;
&#xD;
          -  Patients with active autoimmune anemia or autoimmune thrombocytopenia are NOT eligible&#xD;
&#xD;
          -  Patients who have current active hepatic or biliary disease (with the exception of&#xD;
             patients with Gilbert's syndrome, asymptomatic gallstones, liver involvement by CLL,&#xD;
             or stable chronic liver disease per investigator assessment) are NOT eligible&#xD;
&#xD;
          -  Patients with active chronic or current infections requiring oral or intravenous&#xD;
             antibiotics are NOT eligible for enrollment to the study until resolution of the&#xD;
             infection and completion of therapeutic antibiotics&#xD;
&#xD;
          -  Patients with a past or current second malignancy are NOT eligible aside from the&#xD;
             following exceptions:&#xD;
&#xD;
          -  Patients who have been free of malignancy for at least 5 years&#xD;
&#xD;
          -  Patients who have a history of completely resected basal or squamous cell skin cancer,&#xD;
             successfully treated in situ carcinoma of the breast or cervix, or pre-cancerous&#xD;
             lesions of the colon&#xD;
&#xD;
          -  Patients with known human immunodeficiency virus (HIV) are NOT eligible for the study&#xD;
&#xD;
          -  Patients with history of significant cerebrovascular disease in the past 6 months or&#xD;
             ongoing event with active symptoms or sequelae are NOT eligible for the study&#xD;
&#xD;
          -  Patients with clinically significant cardiac disease including unstable angina, acute&#xD;
             myocardial infarction within six months prior to enrollment, congestive heart failure&#xD;
             (New York Heart Association [NYHA ] III-IV), and arrhythmia unless controlled by&#xD;
             therapy (with the exception of extra systoles or minor conduction abnormalities), are&#xD;
             NOT eligible&#xD;
&#xD;
          -  Patients with significant concurrent, uncontrolled medical condition including, but&#xD;
             not limited to, cardiovascular, renal, hepatic, gastrointestinal, endocrine,&#xD;
             pulmonary, neurological, cerebral or psychiatric disease which in the opinion of the&#xD;
             investigator may represent a risk for the patient, are NOT eligible&#xD;
&#xD;
          -  Patients with positive serology for Hepatitis B (HB), defined as a positive test for&#xD;
             HB surface antigen (HBsAg), are NOT eligible; if negative for HBsAg but HB core&#xD;
             antibody (HBcAb) positive a HB deoxyribonucleic acid (DNA) test will be performed; if&#xD;
             HB DNA test is positive the patient is NOT eligible; NOTE: patients who are positive&#xD;
             for HBcAb but negative for hepatitis B virus (HBV) antigenemia and viremia (HBsAg&#xD;
             negative and HB DNA test negative) may be eligible for the study, but must be started&#xD;
             on HBV suppression therapy with lamivudine or equivalent anti-HBV agents throughout&#xD;
             the treatment and for a year after the completion of the treatments; these patients&#xD;
             need to have liver function tests (LFTs) and HBV viral titer monitoring at least&#xD;
             monthly during the treatment and for a year after treatment completion&#xD;
&#xD;
          -  Patients with positive serology for hepatitis C are NOT eligible&#xD;
&#xD;
          -  Women of childbearing potential and sexually active males must commit to the use of&#xD;
             adequate contraception from the study start to one year after the last dose of study&#xD;
             treatment&#xD;
&#xD;
          -  Childbearing potential is defined as any woman (regardless of sexual orientation,&#xD;
             having undergone a tubal ligation, or remaining celibate by choice) who meets the&#xD;
             following criteria:&#xD;
&#xD;
          -  Has not undergone a hysterectomy or bilateral oophorectomy; or&#xD;
&#xD;
          -  Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has&#xD;
             had menses at any time in the preceding 12 consecutive months)&#xD;
&#xD;
          -  Adequate contraception is defined as hormonal birth control, intrauterine device,&#xD;
             barrier method or total abstinence; patients who are unable or unwilling to use&#xD;
             adequate contraception are NOT eligible&#xD;
&#xD;
          -  Women who are pregnant or lactating are NOT eligible&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shuo Ma, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital Solna</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>May 16, 2011</study_first_submitted>
  <study_first_submitted_qc>May 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2011</study_first_posted>
  <results_first_submitted>December 29, 2020</results_first_submitted>
  <results_first_submitted_qc>December 29, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 22, 2021</results_first_posted>
  <last_update_submitted>December 29, 2020</last_update_submitted>
  <last_update_submitted_qc>December 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Shuo Ma</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antineoplastic Agents, Immunological</mesh_term>
    <mesh_term>Alemtuzumab</mesh_term>
    <mesh_term>Ofatumumab</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Opened for accrual on June 3, 2011 with goal of 60 patients. First patient started treatment June 13, 2011. Accrual was suspended Sep. 26, 2011 for safety analysis of the first 6 patients. The study opened May 4, 2012 for safety cohort of 6 more patients. Study was suspended July 23, 2012 for safety analysis, and opened again Feb 4, 2013. The study closed Sep 13, 2016 because the total accrual goal for Northwestern University was met.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Alemtuzumab + Ofatumumab</title>
          <description>Alemtuzumab: Administered subcutaneously, 3 times per week for up to 18 weeks at a standard dose of 30mg (except for week 1 which will dose escalate from 3mg→10mg→30mg).&#xD;
Ofatumumab: Starting at week 3, administered intravenously on day 1 of every other week prior to alemtuzumab for a total of 8 doses. For week 3 (dose 1) ofatumumab will be given at a dose of 300mg; for weeks 5, 7, 9, 11, 13, 15, and 17 (doses 2-8) ofatumumab will be given at a dose of 2000mg.&#xD;
Toxicity was assessed after completion of the extended safety run-in period of the first 12 patients at an ofatumumab dose of 2000 mg for doses 2-8. Depending on the number of patients who experienced a dose limiting toxicity in the initial 2 safety cohorts, ofatumumab doses 2-8 could have been continued at 2000 mg or reduced to 1000 mg for subsequent patients. Based on the toxicity data of the first 12 patients, ofatumumab doses 2-8 were given at 2000 mg for doses 2-8 for all patients.&#xD;
Based on experience with the initial safety run-in cohort of 6 patients, early stopping is necessary to avoid over-treatment in patients who have achieved a complete remission early. As soon as a patient is determined to have achieved MRD- CR or CRi (per iwCLL2008 criteria), both alemtuzumab and ofatumumab will be stopped.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Trial Entry (Registration)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Patient did not meet Protocol criteria for trial entry</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Week 9 Bone Marrow Response Assessment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Complete Remission in Week 8</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Continued Treatment After 9 Weeks</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Complete Remission in Week 9</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Continued Treatment After 12 Weeks</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Complete Remission in Week 12</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progressive Disease at Week 11</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Completed Week 18 of Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Complete Remission</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>10 Year Follow-up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="52">All patients who receive at least one dose of study drug go into follow-up.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Still in follow-up</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Developed new cancer</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>New treatment started</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progressive Disease and New treatment started</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progressive Disease</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Alemtuzumab + Ofatumumab</title>
          <description>Alemtuzumab: Administered subcutaneously, 3 times per week for up to 18 weeks at a standard dose of 30mg (except for week 1 which will dose escalate from 3mg→10mg→30mg).&#xD;
Ofatumumab: Starting at week 3, administered intravenously on day 1 of every other week prior to alemtuzumab for a total of 8 doses. For week 3 (dose 1) ofatumumab will be given at a dose of 300mg; for weeks 5, 7, 9, 11, 13, 15, and 17 (doses 2-8) ofatumumab will be given at a dose of 2000mg.&#xD;
Toxicity was assessed after completion of the extended safety run-in period of the first 12 patients at an ofatumumab dose of 2000 mg for doses 2-8. Depending on the number of patients who experienced a dose limiting toxicity in the initial 2 safety cohorts, ofatumumab doses 2-8 could have been continued at 2000 mg or reduced to 1000 mg for subsequent patients. Based on the toxicity data of the first 12 patients, ofatumumab doses 2-8 were given at 2000 mg for doses 2-8 for all patients.&#xD;
biopsy: Correlative studies</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="52"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Best Response as Defined by the iwCLL2008 (International Workshop on Chronic Lymphocytic Leukemia 2008)</title>
        <description>CR= Absence of clonal lymphocytes in the peripheral blood, significant lymphadenopathy, hepatomegaly or splenomegaly, and constitutional symptoms. Blood counts: Neutrophils ≥ 1,500/μL; Platelets &gt;100,000μL; Hemoglobin &gt; 11.0g/dL. Bone marrow normocellular for age, less than 30% of nucleated cells = lymphocytes. Lymphoid nodules absent. CRi= Fulfills CR but anemia or thrombocytopenia or neutropenia related to drug toxicity. PR= 2 criteria from group A and 1 from Group B. Group A: Decrease in the number of blood lymphocytes of 50% or more. Reduction in lymphadenopathy. No increase in any lymph node, and no new enlarged lymph node. A decrease in liver by at least 50% from baseline. Decrease in the size of the spleen by 50% or more. Reduction in marrow infiltrate or B-lymphoid nodules. Group B: Platelet counts &gt; than 100,000/μL or 50% better. Hemoglobin &gt; than 11.0g/dL or 50% better. Neutrophils&gt;1500/μL or 50% better. Criteria is continued in Analysis Population Description below...</description>
        <time_frame>Range of responses between 8 weeks from initiation of treatment to 2 months post-treatment.</time_frame>
        <population>Criteria from Outcome Measure Description cont. MRD=Bone marrow with less than one CLL cell per 10,000 leukocytes. To qualify as a PD: at least two of the criteria of in Group A, plus one of the criteria in Group B, must be met. Group A: An increase ≥ 50% of: lymphadenopathy, hepatomegaly, or splenomegaly. An increase ≥ 50% over baseline in blood lymphocytes. Group B: Platelet count decrease of ≥ 50% from baseline secondary to CLL, Hemoglobin decrease of &gt; 2g/dl from baseline secondary to CLL.</population>
        <group_list>
          <group group_id="O1">
            <title>Alemtuzumab + Ofatumumab</title>
            <description>Alemtuzumab: Administered subcutaneously, 3 times per week for up to 18 weeks at a standard dose of 30mg (except for week 1 which will dose escalate from 3mg→10mg→30mg).&#xD;
Ofatumumab: Starting at week 3, administered intravenously on day 1 of every other week prior to alemtuzumab for a total of 8 doses. For week 3 (dose 1) ofatumumab will be given at a dose of 300mg; for weeks 5, 7, 9, 11, 13, 15, and 17 (doses 2-8) ofatumumab will be given at a dose of 2000mg.&#xD;
Toxicity was assessed after completion of the extended safety run-in period of the first 12 patients at an ofatumumab dose of 2000 mg for doses 2-8. Depending on the number of patients who experienced a dose limiting toxicity in the initial 2 safety cohorts, ofatumumab doses 2-8 could have been continued at 2000 mg or reduced to 1000 mg for subsequent patients. Based on the toxicity data of the first 12 patients, ofatumumab doses 2-8 were given at 2000 mg for doses 2-8 for all patients.&#xD;
biopsy: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Best Response as Defined by the iwCLL2008 (International Workshop on Chronic Lymphocytic Leukemia 2008)</title>
          <description>CR= Absence of clonal lymphocytes in the peripheral blood, significant lymphadenopathy, hepatomegaly or splenomegaly, and constitutional symptoms. Blood counts: Neutrophils ≥ 1,500/μL; Platelets &gt;100,000μL; Hemoglobin &gt; 11.0g/dL. Bone marrow normocellular for age, less than 30% of nucleated cells = lymphocytes. Lymphoid nodules absent. CRi= Fulfills CR but anemia or thrombocytopenia or neutropenia related to drug toxicity. PR= 2 criteria from group A and 1 from Group B. Group A: Decrease in the number of blood lymphocytes of 50% or more. Reduction in lymphadenopathy. No increase in any lymph node, and no new enlarged lymph node. A decrease in liver by at least 50% from baseline. Decrease in the size of the spleen by 50% or more. Reduction in marrow infiltrate or B-lymphoid nodules. Group B: Platelet counts &gt; than 100,000/μL or 50% better. Hemoglobin &gt; than 11.0g/dL or 50% better. Neutrophils&gt;1500/μL or 50% better. Criteria is continued in Analysis Population Description below...</description>
          <population>Criteria from Outcome Measure Description cont. MRD=Bone marrow with less than one CLL cell per 10,000 leukocytes. To qualify as a PD: at least two of the criteria of in Group A, plus one of the criteria in Group B, must be met. Group A: An increase ≥ 50% of: lymphadenopathy, hepatomegaly, or splenomegaly. An increase ≥ 50% over baseline in blood lymphocytes. Group B: Platelet count decrease of ≥ 50% from baseline secondary to CLL, Hemoglobin decrease of &gt; 2g/dl from baseline secondary to CLL.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Remission (CR), Minimal Residual Disease (MRD) Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complete Remission (CR), Minimal Residual Disease (MRD) positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complete Remission, MRD status unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complete Remission with Incomplete Marrow Recovery (CRi)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Remission (PR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive Disease (PD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Survival Rates</title>
        <description>Survival rates will be calculated for progression-free survival (PFS), therapy-free survival (TFS), and overall survival (OS).</description>
        <time_frame>Up to 5 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Toxicity as Measured by Adverse Events Experienced While on Treatment</title>
        <time_frame>Weeks 1, 3, 5, 7, 9, 11, 13, 15, and 17</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlation of Disease Characteristics With Disease Outcomes</title>
        <description>Clinical outcomes (such as response, PFS and TFS) will be correlated with pre-treatment clinical and biological characteristics(such as Rai staging, presence of bulky lymph nodes, cytogenetics by FISH, CD38, ZAP70 and IgVH mutation status).</description>
        <time_frame>At baseline and over 18 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Compare Efficacy Between This Study and Historical Control Study of Alemtuzumab-rituximab</title>
        <description>Response and survival rates will be compared between the two studies.</description>
        <time_frame>At baseline and over 18 weeks</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected over a four year period. Each patient was followed from the time of treatment, and during treatment up to 18 weeks. Adverse events were collected up to 60 days post-therapy. Serious adverse events (SAEs) were collected for one year after treatment discontinuation or until the initiation of second-line therapy.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Alemtuzumab + Ofatumumab</title>
          <description>Alemtuzumab: Administered subcutaneously, 3 times per week for up to 18 weeks at a standard dose of 30mg (except for week 1 which will dose escalate from 3mg→10mg→30mg).&#xD;
Ofatumumab: Starting at week 3, administered intravenously on day 1 of every other week prior to alemtuzumab for a total of 8 doses. For week 3 (dose 1) ofatumumab will be given at a dose of 300mg; for weeks 5, 7, 9, 11, 13, 15, and 17 (doses 2-8) ofatumumab will be given at a dose of 2000mg.&#xD;
Toxicity was assessed after completion of the extended safety run-in period of the first 12 patients at an ofatumumab dose of 2000 mg for doses 2-8. Depending on the number of patients who experienced a dose limiting toxicity in the initial 2 safety cohorts, ofatumumab doses 2-8 could have been continued at 2000 mg or reduced to 1000 mg for subsequent patients. Based on the toxicity data of the first 12 patients, ofatumumab doses 2-8 were given at 2000 mg for doses 2-8 for all patients.&#xD;
Based on experience with the initial safety run-in cohort of 6 patients, early stopping is necessary to avoid over-treatment in patients who have achieved a complete remission early. As soon as a patient is determined to have achieved MRD- CR or CRi (per iwCLL2008 criteria), both alemtuzumab and ofatumumab will be stopped.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.03)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal Platelets</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Neutropenic fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Thrombotic thrombocytopenic purpura</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <description>The patient also experienced fever at the time of this event.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>CMV infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>MRSA Bacteremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>CMV positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Prostate Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Diffuse Large B-Cell Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <description>This patient also experienced hypercalcemia at the time of this event.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema multiforme</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.03)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Decreased IgG</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Decreased IgA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Decreased IgM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Diffuse Large B-Cell Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Easy bruising</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Elevated neutrophils</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hemolysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Thrombotic thrombocytopenic purpura</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Left branch bundle block</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Nonspecific T Wave Abnormalities</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Cerumen Impaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Enlarged adrenal glands</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Brown tint to vision</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Double vision</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Keratitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal cramping</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Diverticulosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Gastroesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Gastrointestinal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Chest tightness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Flu like symptoms</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Infusion site extravasation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Itchiness in throat</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Lightheadedness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Night Sweats</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatitis B positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Autoimmune disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Cytokine release syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Elevated Quantitative IgG</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hypogammaglobulinemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>CMV reactivation</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>CMV Infection</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Genital herpes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Legionella Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>MRSA Bacteremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Mucosal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>pneumonia, community acquired</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Abnormal C-reactive protein levels</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Abnormal Hemoglobin count</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Abnormal neutrophil count</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Abnormal platelet count</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Basal Cell Carcinoma Recurrence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>High cholesterol</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Decrease absolute CD3+</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Decrease absolute CD3+CD8+</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Decrease absolute CD3+CD4+</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>decreased hematocrit</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Decreased B cell %</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Elevated LDH</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Enlarged lymph node in left groin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>IgM paraprotein</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Increased C-reactive protein.</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Iron deficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Lymphocyte count increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Ringing in ears</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Rising PSA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Borderline diabetes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Diabetes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Diabetes Mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hyperlipidemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hypermagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hyperuricemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>lack of vitamin B12</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Generalized muscle weakness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hip pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Left lumbar spasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Muscle weakness lower limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Muscle weakness trunk</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pain in shoulder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Worsening of gout</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>polyps</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>surgery to remove two small basiliom</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Concentration impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Peripheral neuropathy in feet</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Restless legs syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Sensory numbness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Tingling in fingertips to elbows</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Tingling in lips</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Decreased urination</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pressure with urination</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Enlargement of prostate gland</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Testicular pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Vaginal Atrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hoarseness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hyposmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Sore throat</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Actinic keratoses</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Cherry angiomas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Erythema multiforme</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Erythematous Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>guttate psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Lower leg lesions</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pain of skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>perivascular dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Petechiae on upper abdomen</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>redness of the skin with scaling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Scalp psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Seborrheic dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Seborrheic keratoses</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Skin tear on right buttock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Spongiotic Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Subacute Spongiotic Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Sun damaged skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Tinea pedis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Tingling in the face</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Laparoscopic appendectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Surgery for testicular varicose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Tonsillectomy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pulmonary emboli</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The participating site (Karolinska University Hospital Solna) did not meet the total accrual goal. However, the lead site (Northwestern University) did.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Shuo Ma, MD, PhD</name_or_title>
      <organization>Northwestern University</organization>
      <phone>312-908-5250</phone>
      <email>shuo-ma@northwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

